Related Party Transactions |
9 Months Ended |
|---|---|
Sep. 30, 2025 | |
| Related Party Transactions [Abstract] | |
| Related Party Transactions | 12. Related Party Transactions A member of the Company's Board of Directors was the chief executive officer of a company that is a vendor of the Company until January 2025. As of December 31, 2024, the Company has recorded $0.5 million in accounts payable and $0.3 million in accrued expense with this vendor in the consolidated balance sheet. The Company has recorded $0.3 million and $0.5 million for the three and nine months ended September 30, 2024, respectively, of expense related to this vendor in the consolidated statement of operations. The chair of the board of directors of BioCryst also serves on the Company’s Board of Directors. The Company has recorded $0.2 million and $81,000 for the three months ended September 30, 2025 and 2024, respectively, and $0.5 million and $0.2 million for the nine months ended in September 30 2025 and 2024, respectively, in license and other revenue in the consolidated statements of operations related to the BioCryst License Agreement. A former member of the Company's Board of Directors is the chief financial officer of Aura Biosciences. The Company has recorded $945 and $4,185 in license and other revenue in the consolidated statement of operations related to the Aura License Agreement for three and nine month periods ending September 30, 2025, respectively. |